Diseño de una formulación de liposomas para la administración de vacunas

  1. DELGADO-RUBIO, Oscar
  2. DE JESUS-VALLE, María José
  3. SANCHEZ-NAVARRO, Amparo 1
  1. 1 Departamento de Farmacia y Tecnología Farmacéutica. Universidad de Salamanca. C/ Méndez Nieto SN. Salamanca
Journal:
Farmajournal

ISSN: 2445-1355

Year of publication: 2016

Volume: 1

Issue: 1

Pages: 53-60

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Farmajournal

Abstract

Antigen is not the single component involved in the pharmacological response for vaccines but additional factors such as formulation and adjuvant compounds play a relevant role. Several strategies based on the use of liposomes are currently assayed in this field. According to this, the aim of the present work was the design, preparation and characterization of a pharmaceutical vehicle able to produce a rapid delivery of adjuvants and a slow release of antigen. From the know-how a theoretical vehicle was design and proposed as optimal formulation and this was then prepared and characterized. The “proposed formulation” is based on albumin coated liposomes made of egg phosphatidylcholine, cholesterol and diethyldodeccyiamonium. The applied procedure carried out in absence of organic solvents allowed for obtaining liposomes with a 20-70 nm aerodynamic diameter range and a zeta potential mean value of 61.9 ±2.08 mV and also for its coating with albumin. Coated particles showed a spherical shape and a size range of 2-10 µm which does not fulfil parenteral formulations requirements but are optimal for nasal or dermatological administration routes.

Bibliographic References

  • Amorij JP, Kersten GF a, Saluja V, Tonnis WF, Hinrichs WLJ, Slütter B, et al. Towards tailored vaccine delivery: Needs, challenges and perspectives. J Control Release. 2012;161(2):363–7.
  • Carmona-Ribeiro AM. Interactions between cationic liposomes and drugs or biomolecules. An Acad Bras Cienc. 2000;72:39–43
  • De Jesús Valle MJ, Sánchez Navarro A. Liposomes Prepared in Absence of Organic Solvents: Sonication Versus Lipid Film Hydration Method. Current Pharm Analysis. 2015;11(2): 86-91
  • Kaur R, Henriksen-Lacey M, Wilkhu J, Devitt A, Christensen D, Perrie Y. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses. Mol Pharm. 2014;11:197–207.
  • Landesman-Milo D, Peer D. Altering the immune response with lipid-based nanoparticles. J Control Release. 2012;161(2):600–8.
  • Perrie Y, Kastner E, Kaur R, Wilkinson A, Ingham AJ. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant. Hum Vaccines Immunother. 2013;9(6):1374–81
  • Smith Korsholm K, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology. 2007;121:216–26.
  • Van Riet E, Ainai A, Suzuki T, Kersten G, Hasegawa H. Combatting infectious diseases; Nanotechnology as a platform for rational vaccine design. Adv Drug Deliv Rev. 2014;74:28–34
Data source: Dialnet